Cybin Inc. (CYBN)
| Bid | 7.25 |
| Market Cap | 153.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -112M |
| EPS (ttm) | -3.46 |
| PE Ratio (ttm) | -2.12 |
| Forward PE | -1.65 |
| Analyst | Buy |
| Ask | 7.5 |
| Volume | 215,203 |
| Avg. Volume (20D) | 278,950 |
| Open | 8.15 |
| Previous Close | 8.16 |
| Day's Range | 7.28 - 8.47 |
| 52-Week Range | 6.50 - 19.84 |
| Beta | 0.98 |
About CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company...
Analyst Forecast
According to 3 analyst ratings, the average rating for CYBN stock is "Buy." The 12-month stock price forecast is $111.5, which is an increase of 1423.22% from the latest price.
1 month ago · businesswire.com
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
2 months ago · businesswire.com
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...